Nebivolol Atb (Nebivolol)

Nebivolol is a selective β1‑adrenergic blocker used in the treatment of cardiovascular conditions related to elevated blood pressure.

• Hypertension: lowers elevated blood pressure and reduces cardiovascular risk in adults.

• Nebivolol selectively antagonizes β1‑adrenergic receptors in cardiac tissue, decreasing heart rate and myocardial contractility. In addition, it stimulates endothelial nitric oxide synthase, leading to nitric‑oxide‑mediated vasodilation, which further contributes to blood pressure reduction without significant β2‑receptor blockade.

Nebivolol may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Headache: mild to moderate headache reported during initial therapy.
• Dizziness: transient light‑headedness, especially when standing quickly.
• Fatigue: general tiredness or reduced energy levels.
• Nausea: occasional upset stomach or feeling of queasiness.
• Bradycardia: slower than normal heart rate.
• Peripheral edema: mild swelling of the ankles or feet.

Serious or Rare Side Effects

• Severe bradycardia: markedly low heart rate requiring medical attention.
• Hypotension: significant drop in blood pressure causing faintness.
• Heart block: impairment of electrical conduction in the heart.
• Bronchospasm: narrowing of airways, particularly in patients with reactive airway disease.
• Allergic reactions: rash, itching, or swelling of the face and throat.
• Cardiogenic shock: rare but life‑threatening cardiac failure.

When prescribing or dispensing Nebivolol, consider the following safety measures.

• Monitor blood pressure: ensure adequate control without excessive lowering.
• Assess heart rate: watch for bradycardia, especially in patients with pre‑existing conduction disorders.
• Use caution in asthma or COPD: β‑blockade may exacerbate bronchospasm.
• Avoid abrupt discontinuation: tapering reduces risk of rebound hypertension.
• Adjust dose in renal impairment: renal function may affect drug clearance.
• Store at ambient temperature: keep in the original pack, protect from moisture.

Nebivolol can interact with several drug classes, influencing its efficacy and safety.

Major Interactions (Avoid)

• Other beta‑blockers: additive bradycardia and hypotension.
• Strong CYP2D6 inhibitors (e.g., paroxetine, quinidine): increased nebivolol plasma concentrations.
• Calcium channel blockers that affect AV node (verapamil, diltiazem): risk of severe bradycardia.

Moderate Interactions (Monitor Closely)

• Diuretics: may enhance antihypertensive effect, requiring blood pressure monitoring.
• Insulin or oral hypoglycemics: nebivolol may mask hypoglycemia symptoms.
• NSAIDs: can reduce the antihypertensive efficacy of nebivolol.